Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: Overall survival data from the phase IIb LUX-Lung 7 trial

dc.contributor.author	O'BYRNE, KEN
dc.date.accessioned	2018-02-27T13:40:35Z
dc.date.available	2018-02-27T13:40:35Z
dc.date.issued	2017
dc.date.submitted	2017	en
dc.identifier.citation	Paz-Ares, L. and Tan, E.-H. and O'Byrne, K. and Zhang, L. and Hirsh, V. and Boyer, M. and Yang, J.C.-H. and Mok, T. and Lee, K.H. and Lu, S. and Shi, Y. and Lee, D.H. and Laskin, J. and Kim, D.-W. and Laurie, S.A. and K??lbeck, K. and Fan, J. and Dodd, N. and M??rten, A. and Park, K., Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: Overall survival data from the phase IIb LUX-Lung 7 trial, Annals of Oncology, 28, 2, 2017, 270-277	en
dc.identifier.other	Y
dc.identifier.uri	http://hdl.handle.net/2262/82626
dc.format.extent	270-277	en
dc.language.iso	en	en
dc.relation.ispartofseries	Annals of Oncology;
dc.relation.ispartofseries	28;
dc.relation.ispartofseries	2;
dc.rights	Y	en
dc.subject	Cancer	en
dc.title	Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: Overall survival data from the phase IIb LUX-Lung 7 trial	en
dc.type	Journal Article	en
dc.type.supercollection	scholarly_publications	en
dc.type.supercollection	refereed_publications	en
dc.identifier.peoplefinderurl	http://people.tcd.ie/obyrneke
dc.identifier.rssinternalid	184823
dc.identifier.doi	http://dx.doi.org/10.1093/annonc/mdw611
dc.rights.ecaccessrights	openAccess

Browse